Genetesis, a Mason, OH-based medical device company focused on using biomagnetic imaging to enable rapid, noninvasive and accurate chest pain triage, closed $7.5M Series A financing.
The round was led by CincyTech with participation from existing investors Mark Cuban’s Radical Investments, and new investors Ohio Innovation Fund and Raptor Group.
The company intends to use the funds to build and install additional CardioFlux™ systems, launch new clinical trials, and prepare for commercial launch.
Led by co-founder and CEO Peeyush Shrivastava, Genetesis is a medical device company creating and developing integrated biomagnetic solutions to improve patients’ health, outcomes, and quality of life.
The company uses biomagnetic imaging, a passive, non-invasive technology with no radiation or exercise required; in combination with proprietary software to detect the presence of ischemic cardiac tissue with a 60- 90 second scan.